ZHONGZHIPHARM (03737) has announced its financial results for 2025. The company reported revenue of approximately 1.737 billion yuan, representing a decrease of 21.6% compared to the previous year. Profit attributable to equity holders was 17.29 million yuan, a significant decline of 81.8% year-on-year. Earnings per share stood at 0.02 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.